Evidence map›Paper›PMID 34189537›Full record

ArticlemedRxiv : the preprint server for health sciences2021

SARS-CoV-2 under an elimination strategy in Hong Kong.

Haogao Gu, Ruopeng Xie, Dillon C Adam, Joseph L-H Tsui, Daniel K Chu, Lydia D J Chang, Sammi S Y Cheuk, Shreya Gurung, Pavithra Krishnan, Daisy Y M Ng and 12 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Haogao Gu *School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Ruopeng Xie *School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Dillon C Adam *School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Joseph L-H Tsui *School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Daniel K Chu *School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Lydia D J ChangSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Sammi S Y CheukSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Shreya GurungSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Pavithra KrishnanSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Daisy Y M NgSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Gigi Y Z LiuSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Carrie K C WanSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Kimberly M EdwardsSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Kathy S M LeungSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Joseph T WuSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Dominic N C TsangCentre for Health Protection, Department of Health, The Government of Hong Kong Special Administrative Region, Hong Kong, China.
Gabriel M LeungSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Benjamin J CowlingSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Malik PeirisSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Tommy T Y LamSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Vijaykrishna DhanasekaranSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Leo L M PoonSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4M
Emerging infections: surveillance, epidemiology and pathogenesisU01AI151810 · NIAID · WASHINGTON UNIVERSITY · PI Adrianus CM Boon, DAVID WANG · 2020 to 2026
$10.0M
NIAID NIH HHS 75N93021C00016NIAID NIH HHS HHSN272201400006CNIAID NIH HHS U01 AI151810
6 · The paper itself

Abstract

Hong Kong utilized an elimination strategy with intermittent use of public health and social measures and increasingly stringent travel regulations to control SARS-CoV-2 transmission. By analyzing >1700 genome sequences representing 17% of confirmed cases from 23-January-2020 to 26-January-2021, we reveal the effects of fluctuating control measures on the evolution and epidemiology of SARS-CoV-2 lineages in Hong Kong. Despite numerous importations, only three introductions were responsible for 90% of locally-acquired cases, two of which circulated cryptically for weeks while less stringent measures were in place. We found that SARS-CoV-2 within-host diversity was most similar among transmission pairs and epidemiological clusters due to a strong transmission bottleneck through which similar genetic background generates similar within-host diversity. ONE SENTENCE SUMMARY: Out of the 170 detected introductions of SARS-CoV-2 in Hong Kong during 2020, three introductions caused 90% of community cases.

Identifiers

PMID34189537
PMCPMC8240692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.